Engflag

Pantomed-40

Quick links to important sections

Pantomed-40

Pantomed-40_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pantomed-40

Quick Facts

Property Description
Active ingredient Pantoprazole (typically as the sodium salt)
Form Delayed-release (enteric-coated) tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Acid suppression therapy
Origin Synthetic compound (substituted benzimidazole)

What Type of Medicine is Pantomed-40?

Pantomed-40 is a specific pharmaceutical preparation containing the active substance Pantoprazole, which is classified as a Proton Pump Inhibitor (PPI), thereby acting as a potent anti-secretory agent. The compound itself is synthetic, originating from the substituted benzimidazole chemical group. The clinical efficacy of Pantoprazole is widely recognized and supported by pharmacological studies for its ability to significantly decrease the amount of acid made in the stomach. This means the medication's overall purpose is to consistently reduce the acid levels in the upper digestive tract, a differentiating factor from older, less potent acid management drugs.

Composition and General Therapeutic Purpose

The medication is supplied as a delayed-release tablet (or enteric-coated tablet), designed for oral administration. Pantoprazole is categorized as an essential medicine required for addressing conditions associated with excessive stomach acid. Since Pantoprazole is sensitive to acid, the enteric coating protects the drug from the highly acidic environment of the stomach, ensuring it remains intact until it reaches the small intestine for absorption. Its general therapeutic purpose is to provide effective and sustained acid suppression, creating a favorable environment that is clinically recognized for aiding the natural healing of irritated tissues in the digestive lining.

What side effects are possible with Pantomed-40?

Possible Side Effects and Safety Information for Pantomed-40

Pantomed-40 (pantoprazole) is associated with documented side effects and requires adherence to specific safety considerations as defined in regulatory labeling. The most common adverse reactions reported (occurring in ge 1% of patients) include headache, diarrhea, nausea, abdominal pain, flatulence, dizziness, and arthralgia.

Clinically Significant and Serious Adverse Reactions

Serious, though rare, adverse events have been reported, primarily concerning hypersensitivity reactions and long-term consequences. These include Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Acute Interstitial Nephritis (AIN), a severe kidney disorder. Pantoprazole therapy is also associated with an increased risk of severe diarrhea due to Clostridium difficile infection (CDAD).

Long-Term Use and Population-Specific Safety

Extended therapy (typically over one year) and/or high doses are associated with several specific risks:

  • Bone Fracture: An increased risk of osteoporosis-related fractures of the hip, wrist, or spine. This risk is highest in older patients (aged 50 years and above) and with prolonged, high-dose use.
  • Hypomagnesemia: Low blood magnesium levels, which can be symptomatic, have been reported after at least three months of treatment.
  • Vitamin B-12 Deficiency: Daily, long-term use (e.g., longer than three years) may lead to malabsorption and deficiency of Vitamin B-12.
  • Fundic Gland Polyps: The risk of developing these benign stomach growths increases with prolonged use, especially beyond one year.

Treatment response to Pantomed-40 does not rule out the presence of a co-existing gastric malignancy. Concomitant use with rilpivirine-containing products is contraindicated. Caution is advised when used in patients with a history of lupus erythematosus (Cutaneous or Systemic), osteoporosis, or hypomagnesemia. Regular monitoring of the International Normalized Ratio (INR) is necessary for patients receiving coumarin anticoagulants like warfarin.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Pantomed-40 (Pantoprazole) overdose, based on government-authorized prescribing information, establishes guidance focused on immediate supportive action. Clinical experience with very high single doses, such as those administered up to 240 mg intravenously, has shown that no specific symptoms of overdose have been reported in humans. Available post-marketing reports of overdose events are generally consistent with the known safety profile of the medication; therefore, the official labeling does not define a unique overdose-specific symptom cluster.

Emergency Action and Procedural Guidance

In the event that an overdose of Pantomed-40 is suspected, the immediate requirement is to seek emergency medical attention. The mandated regulatory action across international authorities is that treatment should be symptomatic and supportive to manage any clinical manifestations that may develop.

Overdose Management Consideration Official Regulatory Statement
Specific Antidote No specific therapeutic recommendations can be made beyond supportive care.
Dialysis Effectiveness Pantoprazole is highly protein bound and is therefore not removed by hemodialysis to any relevant degree.

This official information establishes the required course of action, which centers on providing supportive management. The absence of a specific antidote means clinical focus is directed toward supporting vital physiological functions, with no specific removal procedure available due to the compound's high plasma protein binding.

Therapeutic Uses of Pantomed-40

What Pantomed-40 Treats: Main Uses and Benefits

Pantomed-40 is a medication containing the active substance pantoprazole, which belongs to a class of drugs known as proton pump inhibitors (PPIs). It is primarily used to manage conditions related to excessive gastric acid production in the stomach and the damage this acid can cause to the esophagus and digestive tract.

Main Medical Uses

  • Gastroesophageal Reflux Disease (GERD): Pantomed-40 is used to treat the symptoms of GERD, such as heartburn and acid regurgitation. It is also indicated for the long-term management and prevention of relapse in patients with reflux esophagitis, a condition where the lining of the food pipe becomes inflamed due to acid reflux.
  • Gastric and Duodenal Ulcers: The medication is used to treat active benign gastric ulcers (stomach ulcers) and duodenal ulcers (ulcers in the first part of the small intestine). It helps create an environment conducive to the healing of these sores by reducing acidity.
  • Zollinger-Ellison Syndrome: This is a rare condition where the stomach produces excessive amounts of acid due to tumors in the pancreas or duodenum. Pantomed-40 is used for the long-term treatment of this and other pathological hypersecretory conditions.
  • NSAID-Associated Ulcer Prevention: In patients who require continuous treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and who are at an increased risk of developing gastric complications, this medication may be used to prevent the formation of stomach and intestinal ulcers.
  • Helicobacter pylori Eradication: In combination with appropriate antibiotics, Pantomed-40 is used to treat duodenal ulcers associated with Helicobacter pylori infection, helping to eliminate the bacteria and reduce the risk of ulcer recurrence.

Primary Benefits

  • Reduction of Acid Production: By inhibiting the enzymes in the stomach wall that produce acid, the medication effectively lowers the overall acidity of the digestive system.
  • Symptom Relief: It provides relief from painful symptoms such as burning sensations in the chest and throat, as well as difficulty swallowing associated with acid reflux.
  • Tissue Healing: By maintaining a less acidic environment, it allows the damaged mucous membranes of the esophagus and stomach to heal.
  • Prevention of Complications: Consistent use as prescribed can help prevent more serious complications of chronic acid reflux, such as narrowing of the esophagus or specialized cell changes in the esophageal lining.

Eligibility and Restrictions for Use

Who Can and Cannot Use Pantomed-40?

Eligibility for Pantomed-40 (pantoprazole) is determined by specific population criteria established in official regulatory documents, defining groups for whom the medicine is permitted, restricted, or explicitly contraindicated.

Absolute Non-Eligibility (Contraindications)

Classification Population/Condition
Contraindicated Individuals with known hypersensitivity to pantoprazole, to any substituted benzimidazoles, or to any non-active ingredient in the formulation.
Contraindicated Patients taking specific antiviral drugs, such as rilpivirine-containing products, atazanavir, or nelfinavir, due to significant concerns regarding reduced drug effectiveness.

Age and Life Stage Restrictions

  • Pediatric Use: Use is generally not recommended in children under 12 years of age. Safety and effectiveness are only established for specific short-term treatments in children 5 years of age and older.
  • Adult and Older Adult Use: The medicine is approved for use in adults (18 years and older), and no specific dose adjustment is required for older adults based on age alone.
  • Pregnancy and Lactation: Pantomed-40 is not recommended during pregnancy and breastfeeding, as a risk to the infant cannot be excluded, requiring discontinuation of either the drug or breastfeeding.

Condition-Based Limitations

Use is generally not recommended for patients with severe hepatic (liver) impairment. However, renal (kidney) impairment does not typically require any dose adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Restrictions

Co-administration with certain HIV antiretroviral medicines is formally restricted due to the potential for significant interaction. Regulatory documentation specifies that combining Pantoprazole with agents such as Atazanavir or Nelfinavir is either contraindicated or strongly advised against. This is primarily a pharmacodynamic interaction where the acid-suppressing activity of Pantoprazole elevates gastric pH, resulting in a critical reduction in the plasma concentration (exposure) of these pH-dependent substances, which can compromise their efficacy.

Documented Exposure-Modifying Agents

Other medicinal products whose absorption depends on an acidic gastric environment may also experience reduced exposure when co-administered. These include oral antifungal agents like Ketoconazole and Itraconazole, and certain oral Tyrosine Kinase Inhibitors such as Erlotinib.

Separately, co-administration with high-dose Methotrexate carries the risk of potentially increasing and prolonging the serum concentration of Methotrexate, a pharmacokinetic interaction noted in regulatory labeling. When taken alongside coumarin anticoagulants, such as Warfarin or Phenprocoumon, changes in the International Normalized Ratio (INR) have been reported, necessitating appropriate monitoring.

Metabolism and Other Product Notes

Pantoprazole is primarily metabolized by the CYP2C19 enzyme system, leading to higher exposure in individuals officially classified as poor metabolizers. Regulatory labeling confirms that delayed-release tablets may be taken with or without food and that Antacids do not significantly affect its absorption.

Mechanism of Action

Targeted Inhibition of the Proton Pump

Pantomed-40 (pantoprazole) acts as an irreversible inhibitor that primarily targets the H+/K+-ATPase enzyme system, commonly known as the proton pump, located in the secretory canaliculi of gastric parietal cells. The medication is absorbed as an inactive prodrug, but its mechanism is activated selectively within this highly acidic environment. This pH-dependent transformation converts the molecule into its biologically active sulfenamide metabolite.

Mechanistic Cascade and Physiological Consequence

The active metabolite forms a stable covalent bond with specific cysteine residues on the proton pump structure. This interaction irreversibly blocks the final stage of the gastric acid secretion pathway, halting the transport of hydrogen ions (H^+) into the stomach lumen. The resultant physiological consequence is a significant, sustained suppression of gastric acid output. Since the binding is irreversible, the duration of effect is determined by the biological synthesis rate of new, functional H^+/ K^+-ATPase enzymes, leading to prolonged elevation of intragastric pH.

Dosage and Administration Information

How to use Pantomed-40

The administration of Pantomed-40 follows protocols defining its route, dosage, and timing. The medication is administered by two routes: oral via delayed-release tablets and intravenously (IV) through injection, the latter being reserved for circumstances where the oral route is temporarily not feasible.

Standard dosing for healing Erosive Esophagitis is 40 mg once daily. For long-term maintenance therapy, the dose is often lowered to 20 mg once daily. Higher doses, such as those used for managing pathological hypersecretion like Zollinger-Ellison Syndrome, typically start at 40 mg twice daily and are approved up to a total daily dose of 240 mg, divided throughout the day.

Contextual administration instructions require that the oral tablet be taken 30 minutes before a meal. To preserve the integrity of the specialized enteric coating, the tablet must be swallowed whole with water and must not be split, crushed, or chewed. Specific population rules apply to patients with severe hepatic impairment (liver dysfunction), for whom the maximum recommended dose is restricted to 20 mg once daily. If a dose is missed, it should be taken as soon as remembered, but two doses must not be taken together to compensate. The IV administration protocols require reconstitution and subsequent dilution before the medication is infused over a defined period of 15 minutes.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Pantomed-40 (Pantoprazole)

This summary describes the scope and structure of the clinical research conducted on Pantomed-40 (Pantoprazole). The information is based on findings reported in scientific literature and regulatory documents, focusing on what was studied and where gaps remain, without offering individual clinical advice.

Evidence for Initial Healing of Severe Reflux Damage (Erosive Esophagitis)

Research exploring outcomes for the lining of the food pipe (esophagus) where damage (erosions) has occurred relies primarily on short-term, randomized controlled trials (RCTs). These studies were designed to examine endpoints related to the status of the esophageal lining over fixed intervals, typically 4 to 8 weeks. Researchers monitored the status of the tissues through endoscopic evaluations.

Studies also evaluated patient-reported outcomes related to physical discomfort, such as the frequency and intensity of heartburn and acid regurgitation. The findings describe patterns observed in these studies regarding mucosal status and symptom changes during the observed time period.

Evidence for Long-Term Management and Preventing Relapse

Once the initial study period was complete, the research explored long-term management. Studies in this area primarily involve longitudinal RCTs that track patients over extended observation periods, typically 6 to 12 months. These trials examined how to maintain the observed status of the esophageal lining and prevent the return (relapse) of both the physical damage and the troublesome symptoms. Research contributes to understanding the patterns observed when the medicine is used continuously for maintenance.

Whether these observed patterns continue beyond the one-year mark is not fully established, as long-term data are limited in large, fully controlled studies extending over multiple years. Also, comparative evidence is lacking for direct comparison against all other proton pump inhibitors in this maintenance context.

Research for Managing Severe Acid Overproduction (Zollinger-Ellison Syndrome)

Pantomed-40 was studied for use in very rare conditions like Zollinger-Ellison Syndrome (ZES), which cause pathological gastric hypersecretion. Because these conditions are rare, the research base relies mostly on long-term observational studies and small case series rather than large RCTs. Studies monitored physiological strain by tracking the amount of acid produced, known as Basal Acid Output (BAO), and examined associated outcomes related to physical discomfort, such as pain and diarrhea.

Due to the scarcity of patients, sample sizes were modest, and evidence quality varies across studies. Therefore, certainty remains low compared to common conditions.

Studies on Use in H. pylori Eradication Regimens

The drug was evaluated in studies as a component of specific multi-drug regimens used to address Helicobacter pylori (H. pylori) infection. The research includes RCTs and numerous meta-analyses that examined the success rate of various drug combinations. Findings describe patterns observed in the studies regarding the eradication success rates achieved when the drug was included as the PPI component.

However, the success of these combination regimens is known to be impacted by global antibiotic resistance, meaning evidence quality varies across studies and the consistency of outcomes can differ by geographic location.

Evidence in Specific Patient Groups

Research in older adults explored patterns related to drug exposure and clearance but data on the long-term outcomes in this age group are still being sought. The medication was evaluated in specific pediatric populations under controlled conditions. Data for certain groups remain insufficient for broad conclusions. The existing research often excluded patients with complex conditions, meaning results apply only to the populations studied in the specific trials, and subgroup findings are uncertain for those who were not included in the primary research.

Frequently Asked Questions (FAQ)

Common questions about Pantomed-40 (FAQ)

Q: Is Pantomed-40 the same type of medicine as omeprazole or esomeprazole?

Pantomed-40, which contains the active ingredient pantoprazole, belongs to the same general category of medicines, known as Proton Pump Inhibitors (PPIs). According to official labeling, while they share a pharmacological class and a similar action (reducing stomach acid), pantoprazole is a distinct chemical compound from omeprazole and esomeprazole. They are not the same medicine.

Q: How quickly do people generally notice an effect from Pantomed-40?

Studies and official information indicate that this medication is not designed for immediate symptom relief. People may begin to notice a benefit after approximately one day of starting treatment. The time to full symptomatic relief in studies is often reported to be within one week of continuous therapy.

Q: What are the most commonly reported side effects of Pantomed-40?

In clinical trials, the most frequently reported adverse reactions, meaning those seen in more than 2% of patients, include headache and diarrhea. Other commonly reported effects include nausea, abdominal pain, vomiting, and flatulence. Official documentation lists all known reported effects.

Q: How long do most people typically use Pantomed-40 for their condition?

The duration of use depends on the condition being addressed. For the initial healing of damage to the food pipe, it is typically used for a short time, often up to eight weeks. Maintenance therapy to prevent symptoms from returning has been studied in controlled trials for up to 12 months.

Q: Can Pantomed-40 be used long-term?

The medication is officially indicated for the long-term management of specific, rare conditions that cause severe acid overproduction. For other common conditions, extended use beyond one year is associated with certain risks noted in regulatory documents, such as an increased risk of bone fracture.

Q: Does Pantomed-40 change how other medicines are absorbed?

Yes, official regulatory documents confirm that Pantomed-40 can potentially affect how other medicines are absorbed. Since it significantly lowers the level of acid in the stomach, the acid suppression may lead to a reduction in the amount of certain other medications absorbed, particularly those that require an acidic environment to work.

Q: Can Pantomed-40 cause diarrhea or constipation?

Diarrhea is one of the adverse reactions most frequently reported in clinical studies. Constipation has also been reported in official documents, though it occurs at a lower frequency (less than 2% of patients in trials).

Q: How does Pantomed-40 help with reflux disease (GERD)?

The medicine is classified as an anti-secretory agent. Its mechanism of action is to suppress the final step of acid production in the stomach's parietal cells. This action significantly reduces the overall acid output, helping to reduce irritation and support the natural healing of tissues in the food pipe affected by reflux.

Q: How does Pantomed-40 compare to other acid-reducing medicines?

Pantomed-40 belongs to the Proton Pump Inhibitor (PPI) class. This class is recognized for providing effective and sustained acid suppression, which distinguishes it from older types of acid-reducing medicines, like H2 blockers or simple antacids. Official sources classify it based on its potent action.

Q: Is it safe to use Pantomed-40 during pregnancy or while breastfeeding?

Official regulatory documents indicate that use during pregnancy and breastfeeding is generally not advised. This is because a possibility of risk to the child cannot be definitively excluded based on current available evidence.

Q: What does the term 'erosive esophagitis' mean in relation to Pantomed-40?

This term refers to damage and erosions that have occurred to the inner lining of the food pipe (esophagus) as a result of chronic exposure to stomach acid. Pantomed-40 is officially indicated for the short-term healing and relief of symptoms associated with this specific, acid-related condition.

Q: Why do doctors often prescribe Pantomed-40?

The medicine is prescribed for several officially indicated conditions. These include the short-term healing and maintenance of healing of damage due to erosive esophagitis associated with GERD, and the long-term management of conditions involving pathological acid overproduction.

Q: Does Pantomed-40 cause long-term stomach problems?

Official safety information notes that prolonged use, particularly when extending beyond one year, is associated with a reported increase in the risk of developing fundic gland polyps. These are generally benign (non-cancerous) growths on the lining of the stomach.

Q: Is Pantomed-40 considered an antibiotic?

No, Pantomed-40, containing pantoprazole, is officially classified as a Proton Pump Inhibitor (PPI), which is a drug class dedicated to reducing acid secretion. It is sometimes used as part of a multi-drug regimen that includes antibiotics to help treat a bacterial infection called H. pylori.

Q: Are there specific foods or drinks to avoid while using Pantomed-40?

Official documentation for the oral tablet form states that it may be taken with or without food. There are no specific foods or drinks that are formally listed as required to be avoided while using this medication.

Q: Does Pantomed-40 affect liver function?

Regulatory documents state that for patients who already have severe liver impairment, the dosage is officially restricted. Additionally, monitoring of liver enzymes during therapy is necessary. Regulatory documents mention that a rise in these enzymes may necessitate discontinuation of the medicine.

Q: Can Pantomed-40 be used by people with kidney issues?

Official information indicates that for people with routine impaired renal (kidney) function, no dose adjustment is typically necessary. However, a serious, but rare, kidney disorder called Acute Interstitial Nephritis (AIN) has been noted in postmarketing reports.

Q: Is it common for people to feel tired when starting Pantomed-40?

Symptoms such as fatigue (feeling tired) and a general feeling of being unwell (malaise) have been reported as adverse reactions. These reports come from postmarketing experience, meaning they were noted after the drug was made available, and they are generally not listed as common side effects.

Q: Can I stop taking Pantomed-40 suddenly?

According to official patient information, treatment with this medicine can generally be stopped without needing to gradually reduce the dose beforehand. If the medication has been used for a prolonged period, official information suggests consulting a healthcare professional before making changes.

Q: Is the maximum effect of Pantomed-40 immediate or does it build up over time?

The effect of the drug is not immediate. The mechanism involves the irreversible blocking of acid-producing pumps, and the maximum acid-suppressing effect builds up and lasts until the body creates new functional pumps. Complete relief from symptoms is generally achieved within one week of regular treatment.

Q: Does Pantomed-40 interact with birth control pills?

Official interaction studies have been conducted using combined oral contraceptives. These studies with birth control pills containing levonorgestrel and ethinylestradiol did not reveal any clinically significant interactions.

Q: Can Pantomed-40 affect mood or sleep?

Adverse reactions reported in official documents include depression and vertigo (dizziness) in a small percentage of patients (less than or equal to 2% in clinical trials). Such reactions can sometimes be related to changes in mood or balance.

Q: Is it true that Pantomed-40 might affect magnesium levels?

Yes, regulatory information confirms that low blood magnesium levels (hypomagnesemia) have been reported with this medication. This risk is primarily associated with long-term use, typically after at least three months of continuous treatment.

Q: Is the formulation of Pantomed-40 designed to release the medicine slowly?

Pantomed-40 is supplied as a delayed-release (enteric-coated) tablet. The primary purpose of this design is not slow release, but to protect the drug from being destroyed by stomach acid, ensuring it remains intact until it reaches the small intestine for absorption.

Q: Can Pantomed-40 be taken with food or is it better on an empty stomach?

Official administration instructions can sometimes vary slightly by regulatory agency. One regulatory label states the oral delayed-release tablet may be taken with or without food. Other regulatory instructions specify taking the medicine 30 minutes before a meal. Because regulatory instructions may differ slightly, the specific local product information should be referenced.

Q: Does Pantomed-40 contain any common allergens?

The medicine is formally contraindicated (not allowed) in individuals with known hypersensitivity to the active ingredient, to any related medicines (substituted benzimidazoles), or to any of the non-active ingredients in the formulation. Official documents list all inactive ingredients, which include compounds like mannitol and polysorbate 80.

Q: Is there research looking at the use of Pantomed-40 in specific patient groups?

Yes, official documents summarize research that has been conducted and reported on its use in specific populations. This includes studies in older adults and in certain pediatric populations (children 5 years and older) for specific, limited conditions.

Q: How is the safety of Pantomed-40 monitored after it is made available?

The safety of the medication is continuously monitored by regulatory bodies through a process described as Postmarketing Experience. This process involves collecting and analyzing reports of adverse reactions that occur after the drug has been approved and made available to the general public.

How should Pantomed-40 be stored and disposed of?

How to Store and Dispose of Pantomed-40

The storage and disposal instructions for Pantomed-40 (pantoprazole sodium delayed-release tablets) ensure the stability of the medication and public safety, as defined by regulatory standards.

Official Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing and away from excess moisture and light.
Container Keep in the container it came in, with the cap tightly closed.
Safety Must be kept out of the reach of children.

Disposal Requirements

Unused or expired tablets should preferably be taken to an official drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash. The medication must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pantomed-40 found in:

A-Z Index: